Market key trends:
One of the key trends in the recombinant therapeutic antibodies and proteins market is the rising preference for monoclonal antibodies over conventional therapy. Monoclonal antibodies have gained popularity in the treatment of various conditions such as cancer and autoimmune diseases due to their high specificity and fewer side effects. They target specific proteins and pathways involved in disease pathology. The development and approval of novel monoclonal antibodies for new indications is expected to drive the growth of this market during the forecast period.
Key Takeaways
The global recombinant therapeutic antibodies and proteins market is expected to witness high growth, exhibiting CAGR of 12.2% over the forecast period, due to increasing prevalence of chronic diseases. The market size for 2017 was US$ 91.2 billion.
North America currently dominates the market due to presence of major players and rising healthcare expenditure. However, Asia Pacific region is expected to witness highest CAGR during the forecast period due to growing healthcare infrastructure, increasing disposable incomes and large patient population.
Key players operating in the recombinant therapeutic antibodies and proteins market are Abbott, Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer Inc., and Sanofi S.A. The companies are involved in developing andLaunching innovative biologics for various therapeutic areas through investments in R&D as well as collaborations.
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian